SCHEMBL1674759

SCHEMBL1674759

NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(=O)O)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.53
BLM P54132 1/20 0.53
PMP22 Q01453 1/20 0.53
KMT2A Q03164 1/20 0.53
DPP4 P27487 2/20 0.51
DPP8 Q6V1X1 2/20 0.51
DPP9 Q86TI2 2/20 0.51
BMP1 P13497 1/20 0.45
ENPEP Q07075 5/20 0.43
GNPAT O15228 1/20 0.42
ECE1 P42892 2/20 0.42
GRM8 O00222 1/20 0.41
GRM6 O15303 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GSR P00390 1/20 0.41
CYP1A2 P05177 1/20 0.41
GRIK1 P39086 1/20 0.41
GRM5 P41594 1/20 0.41
GRIA1 P42261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5971672 1.00 ALOX15 (0.53) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL31514361 0.97 ALOX15 (0.50) ALOX15BLMPMP22KMT2ADPP4
Acetic Acid SCHEMBL30311271 0.95 DPP4 (0.51) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL5971152 0.92 KMT2A (0.55) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL20495523 0.92 KMT2A (0.55) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL5971163 0.92 KMT2A (0.55) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL1674757 0.90 DPP4 (0.54) DPP4DPP8DPP9BMP1ENPEP
SCHEMBL29517676 0.90 DPP4 (0.54) DPP4DPP8DPP9BMP1ENPEP
SCHEMBL1674753 0.90 DPP4 (0.54) DPP4DPP8DPP9BMP1ENPEP
SCHEMBL29630381 0.90 BMP1 (0.49) ALOX15BLMPMP22KMT2ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263437-A1 POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 US claimed
US-12377110-B2 Fospropofol methods and compositions EPALEX CORPORATION (US) 2025-08-05 US claimed
EP-4276105-A1 POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd (CN) 2023-11-15 EP claimed
US-20230295233-A1 POLYPEPTIDE FOR REPAIRING MUCOSAL DAMAGE OR SKIN WOUND AND USE THEREOF SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) 2023-09-21 US claimed
CN-116133673-A Polypeptide for repairing mucous membrane injury or skin wound and application thereof 四川好医生攀西药业有限责任公司 2023-05-16 CN claimed
EP-4177259-A1 POLYPEPTIDE FOR REPAIRING MUCOSAL DAMAGE OR SKIN WOUND AND USE THEREOF Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd (CN) 2023-05-10 EP claimed
US-20230084521-A1 PROPOFOL PRODRUG METHODS AND COMPOSITIONS EPALEX CORPORATION 2023-03-16 US claimed
CN-114805489-A Polypeptide for repairing skin injury or mucous membrane injury and application thereof 四川好医生攀西药业有限责任公司 2022-07-29 CN claimed
WO-2022148289-A1 POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF 四川好医生攀西药业有限责任公司 2022-07-14 WO claimed
US-20220105050-A1 PROPOFOL PRODRUG METHODS AND COMPOSITIONS EPALEX CORPORATION 2022-04-07 US claimed
EP-2661266-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES Elcelyx Therapeutics, Inc. (US) 2013-11-13 EP claimed
WO-2012094636-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ELCELYX THERAPEUTICS, INC. (US) 2012-07-12 WO claimed
US-20250346890-A1 LEUKEMIA TREATMENT DEUTSCHES KREBSFORSCH (DE) 2025-11-13 US disclosed
US-20250312361-A1 FOSPROPOFOL METHODS AND COMPOSITIONS EPALEX CORP (US) 2025-10-09 US disclosed
US-20250263437-A1 POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 US disclosed
US-12377110-B2 Fospropofol methods and compositions EPALEX CORPORATION (US) 2025-08-05 US disclosed
WO-2004055048-A2 CHIMERIC ALPHA Q-GUSTDUCIN G-PROTEINS GIVAUDAN SA (CH) 2004-07-01 WO disclosed
US-4975418-A Therapeutically active compositions of pseudo-peptide of glutamyl-aspartic acid CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC (CNRS) (FR) 1990-12-04 US disclosed
EP-0266385-A1 THERAPEUTICALLY ACTIVE PSEUDO-PEPTIDE OF GLUTAMYL-ASPARTIC ACID CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1988-05-11 EP disclosed
WO-1987006931-A1 THERAPEUTICALLY ACTIVE PSEUDO-PEPTIDE OF GLUTAMYL-ASPARTIC ACID CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 1987-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250312361-A1 FOSPROPOFOL METHODS AND COMPOSITIONS FOS, FOSB, PFAS ALOX15 946/4885BLM 1356/4885PMP22 91/4885
US-12377110-B2 Fospropofol methods and compositions FOS, FOSB, PFAS ALOX15 946/4885BLM 1356/4885PMP22 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.